Navigation Links
Targeted therapy reactivates 'guardian of the genome' in resistant cancer
Date:11/15/2010

It is common for cancer cells to find some way to disarm p53, also known as "guardian of the genome" due to its action in preventing defective cells from dividing. "The critical importance of the protective function of p53 is underscored by the diversity of molecular strategies employed by cancer cells to subvert p53 activity, such as overexpression of antagonistic proteins like HDM2 and HDMX," explains senior study author Dr. Loren D. Walensky from Harvard Medical School. "Restoration of p53 activity remains an important goal in the quest for more effective cancer therapeutics."

Previous work demonstrated that selective inhibition of HDM2 restored p53 function in cancer cells. However, these results were often compromised by expression of HDMX. In an earlier study, Dr. Walensky and colleagues described the generation of "stapled" peptides designed to resemble the section of p53 that interacts with HDM2. When biochemical and structural studies revealed that HDM2 and HDMX engage the same region of p53, the researchers examined whether the most effective engineered HDM2 inhibitor (SAH-p53-8) could also interfere with HDMX and how this interaction might influence the p53 activity.

The SAH-p53-8 compound was even more effective at targeting HDMX and effectively blocked formation of the inhibitory p53-HDMX complex, thereby restoring the p53 pathway and reducing tumor cell viability. Importantly, when SAH-p53-8 was delivered intravenously to mice with HDMX-expressing cancer, p53 activity was increased and tumor growth was suppressed.

"We found that targeting HDMX overcame HDMX-mediated p53 suppression and resistance to selective HDM2 inhibition, while dual targeting of HDM2 and HDMX maximized therapeutic reactivation of the p53 tumor suppressor pathway in cancers that express both protein antagonists and retain functional p53," concludes Dr. Walensky. "Importantly, monitoring cellular levels of p53-HDMX complex may be useful for predicting cancer cell susceptibility to HDMX inhibition and determining the efficacy of HDM2 inhibitor-mediated p53 restoration, which forms the basis for enhancing the therapeutic impact of dual HDM2/HDMX targeting in resistant cancers."


'/>"/>

Contact: Elisabeth N. Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. UCI non-small cell lung cancer study highlights advances in targeted drug therapy
2. People with specific kind of lung cancer respond to new targeted treatment
3. Targeted radiation therapy minimizes GI side effects for prostate cancer patients, Penn study shows
4. Highly targeted radiation technique minimizes side effects of prostate cancer treatment
5. Sexual issues a major concern for cancer patients taking new targeted drugs
6. Targeted therapy promising for HER2-positive metastatic breast cancer
7. Evaluation of targeted therapy in ovarian cancer
8. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
9. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
10. Targeted therapy triggers complex mechanism of resistance
11. Synthetic lethality strategy improves molecularly targeted cancer therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest ... centric payment system, to expand its focus on patient care by providing an ... , “At Ogden Clinic, we are working to become a different type ...
(Date:3/23/2017)... ... 23, 2017 , ... “The Trainer”: an electrifying and suspenseful gunslinger novel ... writer with an active imagination and an enthusiasm for action and adventure stories. ... Wild Bill Hart, who sat looking at the thirty-three notches that lined the edges ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider of circulating ... in circulating tumor cells using microfluidic western blotting” in Nature Communications on March ... technology to capture CTCs and a microfluidic single-CTC resolution Western blot from ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... publication of the first issue of its companion print magazine. The new magazine, ... cosmetic surgery thanks to information provided by board-certified doctors from across the country. ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... California Bay Area providing insurance assistance, financial planning, and related services to residents ... Species International to promote awareness of threatened species and wild lands. , Endangered ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... March 23, 2017 On ... the trading session at 5,821.64, up 0.48%; the ... finish at 20,661.30; and the S&P 500 closed ... based as six out of nine sectors ended ... initiated reports coverage on the following Medical Instruments ...
(Date:3/23/2017)... , March 23, 2017 BioLineRx Ltd. ... immunology, announced today that it has acquired Agalimmune Ltd., a ... consideration consisted of a $6 million upfront payment, of which ... shares. Additional future payments may be made based on development ... ...
(Date:3/23/2017)... AVIV, Israel, March 23, 2017  Galmed Pharmaceuticals ... the "Company"), a clinical-stage biopharmaceutical company focused on ... the treatment of nonalcoholic steatohepatitis, or NASH, and ... the three and twelve months ended December 31, 2016, ... completed pre-clinical studies demonstrating Aramchol™,s potential direct effect ...
Breaking Medicine Technology: